Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Histone deacetylase (HDAC) is an emergent anticancer target, and HR23B is a biomarker for response to HDAC inhibitors. We show here that HR23B has impacts on two documented effects of HDAC inhibitors; HDAC inhibitors cause apoptosis in cells expressing high levels of HR23B, whereas in cells with low level expression, HDAC inhibitor treatment is frequently associated with autophagy. The mechanism responsible involves the interaction of HDAC6 with HR23B, which downregulates HR23B and thereby reduces the level of ubiquitinated substrates targeted to the proteasome, ultimately desensitising cells to apoptosis. Significantly, the ability of HDAC6 to downregulate HR23B occurs independently of its deacetylase activity. An analysis of the HDAC6 interactome identified HSP90 as a key effector of HDAC6 on HR23B levels. Our results define a regulatory mechanism that involves the interplay between HR23B and HDAC6 that influences the biological outcome of HDAC inhibitor treatment.

Original publication

DOI

10.1038/cdd.2013.47

Type

Journal article

Journal

Cell Death Differ

Publication Date

10/2013

Volume

20

Pages

1306 - 1316

Keywords

Apoptosis, Autophagy, Biomarkers, Tumor, Cell Line, Tumor, DNA Repair Enzymes, DNA-Binding Proteins, Gene Expression Regulation, Neoplastic, Histone Deacetylase 6, Histone Deacetylase Inhibitors, Histone Deacetylases, Humans, RNA, Small Interfering, Transfection, Ubiquitin